1Ajuebor MN,Swain MG. Role of chemokines and ehemokine receptors in the gastrointestinal tract[J].Immunology,2002.137-143.
2Moiler DE,Flier JS. Insulin resistance mechanisms,syndromes,and implications[J].New England Journal of Medicine,1991.938-948.
3ChaveyC,Fajas L. CXCL5 drives obesity to diabetes,and further[J].Aging (Albany NY),2009.674-677.
4Takahashi M,Takahashi Y,Takahashi K. CXCL14 enhances insulin-dependent glucose uptake in adipocytes and is related to high-fat diet-induced obesity[J].Biochemical and Biophysical Research Communications,2007.1037-1042.
5Hara T,Nakayama Y. CXCL14 and insulin action[J].VITAMINS AND HORMONES-ADVANCES IN RESEARCH AND APPLICATIONS,2009.107-123.
6Nara N,Nakayama Y,Okamoto S. Disruption of CXC motif chemokine ligand-14 in mice Ameliorates obsity-induced insulin resistance[J].Journal of Biological Chemistry,2007.30794-30803.
7Morimoto J,Yoneyama H,Shimada A. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis[J].Journal of Immunology,2004.7017-7024.
8Roep BO,Kleijwegt FS,van Halteren AG. Islet inflammation and CXCL10 in recent-onset type 1 diabetes[J].Clinical and Experimental Immunology,2010.338-343.
9Herder C,Baumert J,Thorand B. Chemokines as risk factors for type 2 diabetes:results from the MONICA/KORA Augsburg study,1984-2002[J].Diabetologia,2006.921-929.
10Herder C,Sehneitler S,Rathmann W. Low grade in flammation,obesity,and insulin resistance in adolescents[J].Endocrinology and Metabolism Clinics of North America,2007.4569-4574.
